Correction: Comparing efficacy and safety of P013, a proposed pertuzumab biosimilar, with the reference product in HER2-positive breast cancer patients: a randomized, phase III, equivalency clinical trial (BMC Cancer
Following publication of the original article [1], the authors identified that Behrouz Najafi was omitted as the third author in the author group. The author group in this correction article has been updated and the original article [1] has been corrected.
ارسال نظر